Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||BGT226||Phase I||Actionable||In a Phase I trial of BGT226 in patients with advanced solid tumors, limited preliminary antitumor activity and inconsistent target inhibition were observed (PMID: 22357447).||22357447|
|Unknown unknown||Advanced Solid Tumor||not applicable||BGT226||Phase I||Actionable||In a Phase I trial, BGT226 treatment was tolerated, and resulted in stable disease as best response in 28% (5/18) of patients with advanced solid tumors (PMID: 31192075).||31192075|
|PubMed Id||Reference Title||Details|
|(22357447)||Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.||Full reference...|
|(31192075)||Larger Valve Size is Associated with Permanent Pacemaker Implantation in Edwards SAPIEN 3™ Transcatheter Aortic Valves.||Full reference...|